Skip to main content

Elutia Inc.

ELUT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001708527

No open-market purchases or sales by Elutia Inc. insiders were filed in the last 90 days; 39 institutions reported holding it in 13F filings for Q2 2026, worth $13.8M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Elutia Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of ELUT: Q2 2023 compared with Q3 2023
MeasureQ2 2023Of which not filed for Q3 2023Q3 2023Change
Holders19121+3
Shares3.06M4.00K6.59M+3.54M (+115.6%)
Value$7.23M$9.44K$9.20M+$1.99M (+27.5%)

1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Elutia Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to ELUT in Q3 2023
InstitutionSharesValue% of portfolio
Nantahala Capital Management, LLC1,650,000$2.36M0.30%
AIGH Capital Management LLC1,764,000$2.30M1.09%
Worth Venture Partners, LLC15,428$22.1K0.01%
JPMorgan Chase & Co3,702$5.29K0.00%
Tower Research Capital LLC (TRC)1,691$2.42K0.00%
Qube Research & Technologies Ltd1$10.00%

Sold out (3)

Institutions that held Elutia Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of ELUT in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Millennium Management LLC13,302$31.4K
Morgan Stanley1,260$2.97K
WealthPLAN Partners, LLC34$80

Not filed for Q3 2023 yet (1)

Institutions that held Elutia Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ELUT in Q2 2023 that haven't filed for Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
BerganKDV Wealth Management, LLC4,000$9.44K